Overcoming ethnic divides key to fueling stock market growth in …

On the heels of President Barack Obama’s trip to Kenya this summer, in which the U.S. president called on Kenya to overcome ethnic divisions, a new study provides insights into the economic cost of segregation in developing countries and how to overcome it.

The study, published in Administrative Science Quarterly, looks at how actors from diverse and competing social groups can […]

How Will China's Stock Market Drop Affect the Rest of Its Economy …

On July 27, the Shanghai Composite Index fell 8.5 percent, its largest single-day loss since 2007. This came on the heels of major government intervention to stem the market’s slide earlier in July. What does the latest chapter of the crash mean for China’s economy? And, more broadly, what does it mean for the policies and politics of China’s current […]

FED Rallies Market But Biotech Stocks Are Lagging

Market Rallies on FED comments but Biotechs are Left Behind
FED Expected to Raise Rates as Labor Market Tightens
The FED stands pat on rates but is on track to raise rates later this year, possibly at the September meeting, as jobs are on track but inflation is still not above 2%. The market began rally at 2P EDT after the FED […]

Cramer: Secret pattern to unlocking biotech riches –

Biotech gains attainable?
Mad Money’s Jim Cramer picked up on a biotech pattern that could benefit your portfolio.
Jim Cramer has picked up on a pattern when it comes to biotech stocks that could change the game for an investor’s portfolio—listen to the darned CEO interviews.In fact, Cramer would argue that the biotech group has gone from being hit or miss to […]

Rayno Biopharma Stocks at ASCO: ARRY, CLVS, RXDX

Biotech Indices Can’t Break Through Triple Top
IBB at $365, XBI at $239
Red and green day
Biotech stocks were mixed today with the major indices holding the flat line. However with all of the clinical data coming out of ASCO (American Society for Clinical Oncology) 2015 in Chicago, IL many “immuno-oncology” stocks were movers.
First look at Rayno Biopharmaceutical Portfolio stocks:
Our big mover […]

Biotech to Remain Strong Because Science is Solid, CEOs Say

Timothy Hay


Biotechnology companies have been going public in record numbers, and many of them have been immediately embraced by public-market investors once their stock starts trading.But does that mean the sector is in a bubble?The chief executives of two venture-backed companies that went public spoke at the National Venture Capital Association’s annual conference in San Francisco. They said the good days for […]

Can Biotech Duplicate Its 2014 Performance, or Is It Time to Jump Ship?

Although biotech stocks as a whole handily outpaced the S&P 500 returns last year, there’s no guarantee that investors will be similarly rewarded this year. To get insight into whether biotech stocks can continue climbing, we asked three top Motley Fool contributors to give us their opinion. Read on to learn what they think.: Bringing a new drug to market […]

Biotech Stocks Are Apparently Immune to Risks of the Day: New Highs Again …Update

Update 1/27 After the Close Amgen Beats
Amgen, Inc (AMGN) fourth quarter earnings and sales beat estimates on strong sales of Enbrel, an arthritis drug.Revenue for Q4 was $5,33B a 6% increase over Q4 2013, The stock was up slightly after hours to $159.40. Sales growth was also driven by Kyprolis and Prolia. The P/S is still a modest 6.12 and […]

Cramer: The biotech that doubled in value last year

This week Jim Cramer has been highlighting the hottest biotech stocks for 2015 as a part of his series “Biotech, the Next Generation.”One of the best performing biotechs for 2014 was the orphan drug company PTC Therapeutics, which rallied 205 percent last year. Shire PLC recently acquired NPS Pharmaceuticals at a 51 percent premium to where it was trading before.This […]

2015 Biotech Stock Preview: Rhythms Of The 'PermaBull' | Seeking …

SummaryBiotech stocks should outperform the market in 2015. However the biotech sector is linked to healthcare fundamentals like government pricing policy.
The industry is better financed than any time in its history driving innovation and new product growth. The appetite for M&A and IPOs will continue.
Biopharmaceutical stocks defy traditional analysis and have been a safe haven from global economic news.
2015: Another […]